Loskog A - Search Results

1

Correction to: Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapy.

Sjöholm T, Korenyushkin A, Gammelgård G, Sarén T, Lövgren T, Loskog A, Essand M, Kullberg J, Enblad G, Ahlström H. Sjöholm T, et al. Among authors: loskog a. Cancer Imaging. 2023 May 19;23(1):46. doi: 10.1186/s40644-023-00548-9. Cancer Imaging. 2023. PMID: 37208774 Free PMC article. No abstract available.

2

Efficient adenovector CD40 ligand immunotherapy of canine malignant melanoma.

von Euler H, Sadeghi A, Carlsson B, Rivera P, Loskog A, Segall T, Korsgren O, Tötterman TH. von Euler H, et al. Among authors: loskog a. J Immunother. 2008 May;31(4):377-84. doi: 10.1097/CJI.0b013e31816a812d. J Immunother. 2008. PMID: 18391758

3

Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia Patients.

Hoffmann JM, Schubert ML, Wang L, Hückelhoven A, Sellner L, Stock S, Schmitt A, Kleist C, Gern U, Loskog A, Wuchter P, Hofmann S, Ho AD, Müller-Tidow C, Dreger P, Schmitt M. Hoffmann JM, et al. Among authors: loskog a. Front Immunol. 2018 Jan 10;8:1956. doi: 10.3389/fimmu.2017.01956. eCollection 2017. Front Immunol. 2018. PMID: 29375575 Free PMC article.

4

Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus.

Diaconu I, Cerullo V, Hirvinen ML, Escutenaire S, Ugolini M, Pesonen SK, Bramante S, Parviainen S, Kanerva A, Loskog AS, Eliopoulos AG, Pesonen S, Hemminki A. Diaconu I, et al. Among authors: loskog as. Cancer Res. 2012 May 1;72(9):2327-38. doi: 10.1158/0008-5472.CAN-11-2975. Epub 2012 Mar 6. Cancer Res. 2012. PMID: 22396493

5

Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4.

Dias JD, Hemminki O, Diaconu I, Hirvinen M, Bonetti A, Guse K, Escutenaire S, Kanerva A, Pesonen S, Löskog A, Cerullo V, Hemminki A. Dias JD, et al. Among authors: loskog a. Gene Ther. 2012 Oct;19(10):988-98. doi: 10.1038/gt.2011.176. Epub 2011 Nov 10. Gene Ther. 2012. PMID: 22071969

6

Adenovirus CD40 ligand gene therapy counteracts immune escape mechanisms in the tumor Microenvironment.

Loskog A, Dzojic H, Vikman S, Ninalga C, Essand M, Korsgren O, Totterman TH. Loskog A, et al. J Immunol. 2004 Jun 1;172(11):7200-5. doi: 10.4049/jimmunol.172.11.7200. J Immunol. 2004. PMID: 15153545

7

CpG oligonucleotide therapy cures subcutaneous and orthotopic tumors and evokes protective immunity in murine bladder cancer.

Ninalga C, Loskog A, Klevenfeldt M, Essand M, Tötterman TH. Ninalga C, et al. Among authors: loskog a. J Immunother. 2005 Jan-Feb;28(1):20-7. doi: 10.1097/00002371-200501000-00003. J Immunother. 2005. PMID: 15614041

8

The immunotherapy of prostate and bladder cancer.

Totterman TH, Loskog A, Essand M. Totterman TH, et al. Among authors: loskog a. BJU Int. 2005 Oct;96(5):728-35. doi: 10.1111/j.1464-410X.2005.05772.x. BJU Int. 2005. PMID: 16144528

9

Adenovirus-mediated CD40 ligand therapy induces tumor cell apoptosis and systemic immunity in the TRAMP-C2 mouse prostate cancer model.

Dzojic H, Loskog A, Tötterman TH, Essand M. Dzojic H, et al. Among authors: loskog a. Prostate. 2006 Jun 1;66(8):831-8. doi: 10.1002/pros.20344. Prostate. 2006. PMID: 16491482

10

CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity.

Mangsbo SM, Ninalga C, Essand M, Loskog A, Tötterman TH. Mangsbo SM, et al. Among authors: loskog a. J Immunother. 2008 Jan;31(1):34-42. doi: 10.1097/CJI.0b013e3181587d29. J Immunother. 2008. PMID: 18157010

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

86 results

Search Page